We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
-16.09%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$1.65B
AUM Growth
-$1.07B
Cap. Flow
-$484M
Cap. Flow %
-29.24%
Top 10 Hldgs %
45.81%
Holding
77
New
–
Increased
10
Reduced
34
Closed
14

Top Buys

Rank Stock Value
1
REPL icon
Replimune Group
REPL
+$12.8M
2
COGT icon
Cogent Biosciences
COGT
+$6.35M
3
ESTA icon
Establishment Labs
ESTA
+$5.01M
4
ANNX icon
Annexon
ANNX
+$4.78M
5
ISRG icon
Intuitive Surgical
ISRG
+$4.1M

Top Sells

Rank Stock Value
1
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$83.3M
2
KRYS icon
Krystal Biotech
KRYS
+$81.8M
3
ABT icon
Abbott
ABT
+$29.8M
4
ALGN icon
Align Technology
ALGN
+$28.6M
5
FOLD
Amicus Therapeutics
FOLD
+$27.3M

Sector Composition

Rank Sector Weight
1 Healthcare 99.13%
2 Industrials 0.87%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ABSI icon
26
Absci
ABSI
$1.49B
$25.4M 1.54%
8,253,316
– –
KROS icon
27
Keros Therapeutics
KROS
$219M
$25.2M 1.53%
552,506
– –
ALXO icon
28
ALX Oncology
ALXO
$277M
$24.3M 1.47%
4,036,451
-290,058
-7% -$3.57M
FDMT icon
29
4D Molecular Therapeutics
FDMT
$810M
$22.5M 1.36%
1,073,435
-187,992
-15% -$4.72M
STTK icon
30
Shattuck Labs
STTK
$707M
$21.7M 1.31%
5,615,489
– –
IGMS
31
DELISTED
IGM Biosciences
IGMS
$21.1M 1.28%
3,072,478
– –
IMVT icon
32
Immunovant
IMVT
$8.51B
$19M 1.15%
720,177
-249,444
-26% -$7.1M
ISRG icon
33
Intuitive Surgical
ISRG
$132B
$17.7M 1.07%
39,843
+10,297
+35% +$4.1M
AUGX
34
DELISTED
Augmedix, Inc. Common Stock
AUGX
$14.4M 0.87%
16,380,327
– –
ETNB
35
DELISTED
89bio
ETNB
$14M 0.85%
1,745,656
-518,910
-23% -$4.63M
ARDX icon
36
Ardelyx
ARDX
$984M
$13.9M 0.84%
1,881,501
-313,059
-14% -$2.2M
SYK icon
37
Stryker
SYK
$127B
$13.4M 0.81%
39,483
-3,763
-9% -$1.27M
PRME icon
38
Prime Medicine
PRME
$655M
$10.7M 0.64%
2,074,350
– –
BPMC
39
DELISTED
Blueprint Medicines
BPMC
$10.2M 0.62%
94,405
-18,655
-17% -$1.87M
ESTA icon
40
Establishment Labs
ESTA
$2.11B
$9.68M 0.59%
213,024
+98,683
+86% +$5.01M
NUVB icon
41
Nuvation Bio
NUVB
$2.34B
$8.85M 0.54%
3,031,009
– –
TRDA icon
42
Entrada Therapeutics
TRDA
$273M
$7.99M 0.48%
560,971
-722,764
-56% -$10.3M
ACIU icon
43
AC Immune
ACIU
$263M
$7.21M 0.44%
1,807,704
-199,327
-10% -$659K
VERV
44
DELISTED
Verve Therapeutics
VERV
$7.14M 0.43%
1,463,406
-141,109
-9% -$887K
RPTX
45
DELISTED
Repare Therapeutics
RPTX
$6.41M 0.39%
1,942,555
-73,747
-4% -$263K
CYTK icon
46
Cytokinetics
CYTK
$10B
$6.06M 0.37%
111,867
-49,733
-31% -$3M
VTYX
47
DELISTED
Ventyx Biosciences
VTYX
$5M 0.3%
2,164,126
– –
BOLD
48
Boundless Bio
BOLD
$64.4M
$4M 0.24%
1,034,583
-79,451
-7% -$759K
ATRA icon
49
Atara Biotherapeutics
ATRA
$92.3M
$3.84M 0.23%
452,270
+81,738
+22% +$1.23M
STXS icon
50
Stereotaxis
STXS
$145M
$3.84M 0.23%
2,108,219
-1,200,579
-36% -$2.69M
1
2
3 4

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q2 2024 Portfolio in Review

As of Q2 2024, Redmile Group held 77 positions worth $1.65B, down 39% from $2.72B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Redmile Group withdrew a net $484M in Q2 2024, closing 14 positions and reducing 34 holdings. Its most notable exit was Deciphera Pharmaceuticals, Inc. Common Stock, an estimated $83.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 98% a quarter earlier, followed by Industrials.

Against the trend, Redmile Group added an estimated $12.8M to Replimune Group.

  • Redmile Group added most to Replimune Group in Q2 2024, an estimated $12.8M increase.
  • Redmile Group's biggest Q2 2024 reduction was Krystal Biotech, cutting an estimated $81.8M.
  • Redmile Group fully exited Deciphera Pharmaceuticals, Inc. Common Stock in Q2 2024, selling an estimated $83.3M.
  • Redmile Group's ten largest holdings make up 46% of its $1.65B portfolio in Q2 2024.
  • Redmile Group opened 0 new positions and closed 14 in Q2 2024.
  • Redmile Group's portfolio value fell 39% quarter-over-quarter to $1.65B.

Based on Redmile Group's 13F filing for Q2 2024, filed 14 Aug 2024.